Shopping Cart
Remove All
Your shopping cart is currently empty
VI-60 is an orally active dual inhibitor of cPLA2 and COX-2, exhibiting anti-inflammatory properties by suppressing the p38 MAPK/cPLA2/COX-2/PGE2 pathway.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | VI-60 is an orally active dual inhibitor of cPLA2 and COX-2, exhibiting anti-inflammatory properties by suppressing the p38 MAPK/cPLA2/COX-2/PGE2 pathway. |
| In vitro | VI-60 (10 μM, 24-48 h) suppresses the production of LPS-induced inflammatory mediators NO (with an IC50 of 3.85 μM) and PGE2, without showing significant cytotoxicity in RAW264.7 cells. |
| In vivo | VI-60 (20 mg/kg, administered orally, daily or every other day) alleviates adjuvant-induced arthritis and exhibits analgesic effects in Lewis rats. When given daily at the same dose, VI-60 modulates the balance of Th17 and Tregs by inhibiting the p38 MAPK/cPLA2/COX-2/PGE2 pathway and reduces IL-17 expression. In Wistar rats, VI-60 presents a low probability of ulceration at 50 mg/kg and shows no hepatotoxicity or nephrotoxicity at a dose of 20 mg/kg administered orally. |
| Formula | C37H43F3O3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.